Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet
Scinai Immunotherapeutics (NASDAQ: SCNI) reported its H1 2025 financial results, showcasing growth in its CDMO business. Revenues reached $773,000, up from $284,000 in H1 2024, while net loss decreased to $4.13 million from $4.48 million.
The company strengthened its balance sheet through a $4.2 million raise via its Standby Equity Purchase Agreement. CDMO operations generated $1.0 million in total orders for 2025, with $850,000 already invoiced. R&D initiatives include advancing anti-IL-17 NanoAb programs, pursuing EU grant funding, and exploring an acquisition opportunity with PinCell srl.
Scinai Immunotherapeutics (NASDAQ: SCNI) ha pubblicato i risultati finanziari del primo semestre 2025, evidenziando una crescita nel business CDMO. I ricavi sono saliti a $773.000, rispetto a $284.000 nel primo semestre 2024, mentre la perdita netta si è ridotta a $4,13 milioni da $4,48 milioni.
L’azienda ha rafforzato il proprio bilancio grazie a una raccolta di $4,2 milioni tramite il Standby Equity Purchase Agreement. Le attività CDMO hanno generato $1,0 milione di ordini totali per il 2025, di cui $850.000 già fatturati. Le iniziative di R&S comprendono l’avanzamento dei programmi anti-IL-17 NanoAb, la ricerca di finanziamenti UE e l’esplorazione di una possibile acquisizione di PinCell srl.
Scinai Immunotherapeutics (NASDAQ: SCNI) presentó sus resultados financieros del primer semestre de 2025, mostrando crecimiento en su negocio CDMO. Los ingresos alcanzaron $773,000, frente a $284,000 en el primer semestre de 2024, mientras que la pérdida neta se redujo a $4.13 millones desde $4.48 millones.
La compañía fortaleció su balance mediante una captación de $4.2 millones a través del Standby Equity Purchase Agreement. Las operaciones CDMO generaron $1.0 millón en pedidos totales para 2025, de los cuales $850,000 ya fueron facturados. Las iniciativas de I+D incluyen el avance de los programas anti-IL-17 NanoAb, la búsqueda de financiación de la UE y la exploración de una posible adquisición de PinCell srl.
Scinai Immunotherapeutics (NASDAQ: SCNI)는 2025년 상반기 실적을 발표하며 CDMO 사업의 성장을 시사했습니다. 매출은 $773,000로 2024년 상반기의 $284,000에서 증가했고, 순손실은 $4.13백만으로 $4.48백만에서 감소했습니다.
회사는 Standby Equity Purchase Agreement를 통해 $4.2백만을 조달하여 재무구조를 강화했습니다. CDMO 운영은 2025년 총 $1.0백만의 주문을 창출했으며, 이 중 $850,000는 이미 청구되었습니다. 연구개발 활동으로는 항-IL-17 NanoAb 프로그램의 진전, EU 보조금 확보 추진, 그리고 PinCell srl 인수 가능성 검토가 포함됩니다.
Scinai Immunotherapeutics (NASDAQ: SCNI) a publié ses résultats financiers du premier semestre 2025, montrant une croissance de son activité CDMO. Les revenus ont atteint 773 000 $, contre 284 000 $ au S1 2024, tandis que la perte nette est passée à 4,13 millions $ contre 4,48 millions $.
La société a renforcé son bilan grâce à une levée de 4,2 millions $ via un Standby Equity Purchase Agreement. Les opérations CDMO ont généré 1,0 million $ de commandes totales pour 2025, dont 850 000 $ déjà facturés. Les initiatives R&D comprennent l'avancement des programmes NanoAb anti-IL-17, la recherche de financements de l'UE et l'exploration d'une opportunité d'acquisition de PinCell srl.
Scinai Immunotherapeutics (NASDAQ: SCNI) hat seine Finanzergebnisse für das erste Halbjahr 2025 vorgelegt und ein Wachstum im CDMO-Geschäft ausgewiesen. Die Umsatzerlöse stiegen auf $773.000 gegenüber $284.000 im ersten Halbjahr 2024, während der Nettoverlust auf $4,13 Millionen von $4,48 Millionen sank.
Das Unternehmen stärkte seine Bilanz durch eine Kapitalaufnahme von $4,2 Millionen im Rahmen eines Standby Equity Purchase Agreement. Die CDMO-Aktivitäten generierten $1,0 Million Gesamtaufträge für 2025, davon wurden bereits $850.000 in Rechnung gestellt. Die F&E-Initiativen umfassen die Weiterentwicklung der Anti-IL-17 NanoAb-Programme, die Beantragung von EU-Fördermitteln und die Prüfung einer Übernahmeoption von PinCell srl.
- None.
- Low cash position of $989,000 as of June 30, 2025
- Marketing, general and administrative expenses increased by 25% to $1.26 million
- Dependent on future grant funding for clinical trials
- Continued operating losses
Insights
Scinai shows 172% CDMO revenue growth amid reduced R&D expenses, with a strengthened cash position but continued operational losses.
Scinai's H1 2025 results reveal a 172% year-over-year revenue increase to
Despite this revenue growth, Scinai remains in a loss-making position with a net loss of
The company's cash position was concerning at just
On the development front, Scinai is pursuing an interesting dual approach with their anti-IL-17 NanoAb program, targeting both localized and systemic psoriasis treatments. Their strategy of pursuing European grant funding (
Six-Month 2025 Financial Summary
- Revenues for the six months ended June 30, 2025, totaled
$773 thousand $284 thousand - R&D expenses for the six months ended June 30, 2025, amounted to
$1,237 thousand $2,788 thousand - Marketing, general and administrative expenses were
$1,256 thousand $1,003 thousand - Net loss was
$4,134 thousand $4,481 thousand - Cash - as of June 30, 2025, cash and cash equivalents totaled
$989 thousand $4.2 million
Business Update
CDMO
- Scinai Bioservices, the Company's CDMO business unit, continues to grow steadily, with its
U.S. subsidiary contributing$421 thousand - As of August 31, 2025, total CDMO service orders for 2025 reached
$1.0 million $850 thousand
R&D
- Scinai is advancing its anti-IL-17 NanoAb program with two product profiles in development: one focused on localized treatment of psoriasis patients with small but debilitating lesions, and another aimed at systemic treatment of moderate-to-severe plaque psoriasis through an innovative tri-specific antibody design.
- The Company plans to apply for up to
€15 million in grant financing under the EU STEP program, with a decision expected in Q1 2026, to fund Phase 1/2a clinical trials. - In 2025, Scinai filed patents for four additional NanoAbs from its collaboration with the Max Planck Society and University Medical Center Göttingen and is exercising its exclusive option to license them. By October 2025, the Company expects to apply for a European Funds for a Modern Economy (FENG) grant to support the development of a novel multi-specific antibody targeting TH2-related diseases such as asthma, atopic dermatitis, and COPD.
- In March 2025, Scinai signed an option agreement to acquire PinCell srl, an Italian biotech company developing PC111, a potential treatment for severe dermatological conditions. A related
€12 million FENG grant application is under review, with a funding decision expected in Q3 2025.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of VHH antibody fragments (nanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical cGMP manufacturing, and pre-clinical and clinical trial design and execution services for early stage biotech drug development projects.
Company website: www.scinai.com
Company Contacts
Investor Relations - Allele Capital Partners | +1 978 857 5075 | aeriksen@allelecapital.com
Business Development | +972 8 930 2529 | bd@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to; the risk that the Company will otherwise be unable to remain compliant with the continued listing requirements of Nasdaq; lower than anticipated revenues of Scinai's CDMO business in 2025 and thereafter; failure to sign agreements with other potential clients of the CDMO business; the risk that the Company will not be awarded, or there will be delays in decisions with respect to, the potential grants from the FENG program, the EU Step program and/or the IIA; that the Company will not exercise its right to acquire PinCell; a delay in the commencement and results of pre-clinical and clinical studies, including the Phase 1/2a study for psoriasis, the risk of delay in, Scinai's inability to conduct, or the unsuccessful results of, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not be successful in expanding its CDMO business or in-license other nanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of nanoAbs will not be met or that Scinai will not be successful in bringing the nanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for nanoAbs, if any; the risk that our business strategy may not be successful; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in
Logo: https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/scinai-reports-six-month-2025-financial-results-highlighting-continued-cdmo-revenue-growth-and-strengthened-balance-sheet-302543710.html
SOURCE Scinai Immunotherapeutics Ltd.
FAQ
What were Scinai's (NASDAQ:SCNI) revenue and net loss figures for H1 2025?
How much funding did Scinai (SCNI) raise in July-August 2025?
What is the status of Scinai's CDMO business in 2025?
What are Scinai's main R&D programs in development?
How much grant funding is Scinai pursuing for clinical trials?
